Conversely, treatment with synthetic specific FXR agonists improved insulin sensitivity in rodents [6,8], and in patients with non-alcoholic fatty liver disease [16]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.